- 1 Interaction between placental efflux transporters and use of antiseizure or
- 2 antidepressant drugs during pregnancy on birth weight in the Norwegian Mother,
- 3 **Father and Child Cohort Study**
- Marta H. Hernandez^{1,2*}, Jacqueline M. Cohen^{1,3}, Karoline H. Skåra^{1,4}, Thea K. 5
- Grindstad¹, Yunsung Lee ¹, Per Magnus ¹, Pål R. Njølstad ^{5,6}, Ole A. Andreassen ^{7,8}, 6
- Elizabeth C. Corfield 9,10, Alexandra Havdahl 9,10,11,12, Espen Molden 13,14, Kari Furu 1,3, 7
- 8 Maria C. Magnus 11, Alvaro Hernaez 1,21
- 10 1. Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo,
- 11 Norway.

- 12 2. Blanquerna School of Health Sciences, University Ramon Llull, Barcelona,
- 13 Spain.
- 3. Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, 14
- 15 Norway.
- 16 4. Department of Community Medicine and Global Health, Institute of Health and
- 17 Society, University of Oslo, Oslo, Norway.
- 5. Center for Diabetes Research, Department of Clinical Science, University of 18
- 19 Bergen, Bergen, Norway
- 20 6. Children and Youth Clinic, Haukeland University Hospital, Bergen, Norway
- 21 7. Norwegian Centre for Mental Disorders Research, NORMENT, Division of Mental
- 22 Health and Addiction, Oslo University Hospital, Oslo, Norway
- 23 8. Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- 24 9. Center for Genetic Epidemiology and Mental Health, Norwegian Institute of Public
- 25 Health, Oslo, Norway
- 10. Nic Waals Institute, Lovisenberg Diakonale Hospital, Oslo, Norway 26
- 27 11. PROMENTA Research Center, Department of Psychology, University of Oslo,
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. OSIO, NOTWAV 28

29 12. MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom 30 13. Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway. 31 14. Section for Pharmacology and Pharmaceutical Department of Pharmacy, 32 University of Oslo, Oslo, Norway 33 34 ¶: both authors contributed equally to this work. 35 36 *Corresponding author 37 E-mail: martahh1@blanquerna.url.edu (MHH)

perpetuity.
All rights reserved. No reuse allowed without permission.

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

MBRN.

ABSTRACT (286 words) Background: Intrauterine exposure to antiseizure and antidepressant drugs is associated with adverse pregnancy outcomes, including low birth weight. Gene variants in placental efflux transporter genes may alter foetal exposure to these drugs. Methods: We investigated whether genetic variants in placental efflux transporters modified the impact of maternal antiseizure and antidepressant drug use on offspring birth weight, using data from the Norwegian Mother, Father and Child Cohort Study and the Medical Birth Registry of Norway (69,828 offspring with their genotype data, 81,189 with maternal genotype data). We systematically searched for gene variants in placental efflux transporters influencing drug exposure [MDR1-ABCB1 (7 alleles), MRP1-ABCC1 (2), MRP2-ABCC2 (3) and, BCRP-ABCG2 (2)] and calculated genetic scores (sum of alleles potentially related to low transporter activity). We assessed the interaction between prenatal drug use and genetic scores on birth weight. Findings: Prenatal antiseizure medication exposure was associated with lower birth weight (-95.5 grams, 95% CI -190 to -0.78). This relationship depended on the offspring's MRP2-ABCC2 genetic score. Birth weight differences between exposed vs. unexposed were 70.3 g (95% CI -494 to 634) in the lowest genetic score category and -306 g (95% CI -361 to -31.8) in the highest (interaction p-value = 0.019; main variant: rs3740066). The antiseizure medication-lower birth weight association also depended on the maternal MDR1-ABCB1 genetic score. Birth weight differences between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category and -317 g (95% CI -517 to -117) in the highest (interaction p-value = 0.037; main variants: rs10248420 and rs2235015). Prenatal antidepressant exposure was associated with low birth weight, but no gene-drug interactions were observed. Conclusions: MRP2-ABCC2 and MDR1-ABCB1 variants may influence prenatal antiseizure medication's impact on neonatal birth weight. **Keywords:** antiseizure medication, birth weight, MRP2-ABCC2, MDR1-ABCB1, MoBa,

SUMMARY

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

What is already known on this topic.

- Low birth weight increases the risk of neonatal death, morbidity, and lifelong susceptibility to various health conditions, including neurodevelopmental, cardiometabolic, respiratory, and psychiatric disorders.
- Previous studies have reported an association between maternal use of centrally acting medication during pregnancy and low birth weight in the offspring, but the underlying causes remain poorly understood.
- It is of great concern to identify strategies that can modulate foetal exposure to these medications and enable individualised, safe use since discontinuation may also increase the risk of harm to the mother.

What this study adds.

- Our study uncovered genetic variants in both offspring (rs3740066) and mother (rs10248420 and rs2235015) linked to placental efflux transporters that modulated the association between maternal antiseizure drug use during pregnancy and the risk of low birth weight in the offspring, marking the first exploration of such interactions.
- If these findings are confirmed and information about specific drugs is incorporated, this could potentially be used in the development of personalized recommendations for pregnant women undergoing these treatments.

INTRODUCTION

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

The use of medication during pregnancy must carefully balance benefits to the mother and potential harm to the offspring.1 Centrally acting drugs (such as antiseizure drugs [mainly lamotrigine, 0.3% of pregnancies] and antidepressants [1.5% of pregnancies]) have been increasingly used during pregnancy.^{2,3} However, intrauterine exposure to these medications may be associated with adverse pregnancy outcomes such as impaired foetal growth and reduced birth weight in offspring.4-6 Furthermore, these conditions are linked to a multitude of morbidities, resulting in both immediate and longterm adverse consequences for newborns, their families, and society. The placenta plays an essential role in substance exchange between mother and foetus (e.g., nutrients, metabolic by-products). Small, non-polar, lipophilic xenobiotics such as antiseizure drugs and antidepressants can pass through the placenta via passive diffusion.8 However, several active proteins can efflux these compounds from the foetus back to the mother.9 Active efflux proteins from the adenosine triphosphate-binding cassette superfamily (such as P-glycoprotein, breast cancer resistance protein, and others multidrug resistance proteins) are involved in the transplacental passage of drugs particularly affecting the passage of centrally-acting drugs and their metabolites. 10,11 Several antiseizure drugs and antidepressants are substrates for these transporters. 12,13 Efflux transporters may therefore have a foetoprotective effect by lowering the concentrations of potentially toxic drugs on the foetal side. Genetic variants in the transporters may modify their activity and could be located in the offspring or maternal genotype. 14,15 Little is known about the role of genetic variants in placental efflux transporters on the modulation of the association of antiseizure drugs and antidepressants during pregnancy with offspring outcomes such as low birth weight.

Our aim was to explore whether there is an interaction between the use of antiseizure drugs or antidepressants during pregnancy and genetic variants related to

115 placental efflux transporters (in P-glycoprotein, breast cancer resistance protein, and

116 others multidrug resistance proteins) on offspring birth weight.

MATERIALS AND METHODS

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

Study participants We included participants in the Norwegian Mother, Father, and Child Cohort Study (MoBa). MoBa is a prospective, population-based pregnancy cohort conducted by the Norwegian Institute of Public Health. Pregnant women and their partners were recruited across Norway between 1999-2008 at the time of routine ultrasound screening (~17th gestational week). The cohort includes approximately 114,000 children, 95,000 mothers, and 75,000 fathers. This work used a subsample of offspring from singleton pregnancies with available information on genotype and birth weight (from version #12 of the qualityassured data files released on May 11, 2022). Genotype data was obtained from blood samples provided during pregnancy and at birth (mothers) and umbilical cord blood at birth (offspring).16 A total of 238,001 samples have been genotyped in 24 genotyping batches with varying selection criteria, genotyping platforms, and genotyping centres. 17 Quality control, phasing, and imputation were performed using the MoBaPsychGen pipeline as previously described. 17 Our work is described according to the Strengthening the Reporting of Observational studies in Epidemiology guidelines (Supplemental Table 3). 18 Use of centrally acting drugs We used self-reported information on the use of centrally acting drugs from MoBa questionnaires in the 18th and 30th gestational weeks. 19 Specifically, women were asked whether they had epilepsy or depression, and if they answered yes, whether any medications were used to treat the condition(s). This project has no information on the specific drug(s) the woman used. Any reported use of medication(s) for epilepsy (yes/no) or depression (yes/no) were categorized and evaluated separately.

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

Birth weight Data on offspring birth weight in grams was obtained from the Medical Birth Registry of Norway, a national health registry which contains information about all births in Norway since 1967.20 Covariates Information on maternal age at delivery (continuous), parity $(1, 2, 3, \ge 4)$ and sex of the offspring (female/male) was obtained from the birth registry. Furthermore, information on maternal years of education (continuous), pre-pregnancy body mass index (continuous), having ever smoked (yes/no), and self-reported depression or epilepsy was gathered in the questionnaire administered at gestational week 18. Genetic variants related to placental transporters and genetic scores. We performed a systematic review in PubMed, Web of Science, pharmacogenetic websites (https://www.pharmgkb.org) and GWAS catalog (https://www.ebi.ac.uk/gwas/) to identify gene variants on the adenosine triphosphate-binding cassette superfamily of placental efflux transporters (MDR1-ABCB1, MRP1-ABCC1, MRP2-ABCC2, and BCRP-ABCG2). We followed the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement.²¹ A detailed description of the search is available in Supplemental Materials. After the systematic review, we only conserved genetic variants that were not in linkage disequilibrium according to linkage disequilibrium block analysis in the 1000 Genomes CEU and GBR populations (given the MoBa participants passing the postimputation quality control cluster with these populations; $R^2 < 0.8$) and with a minor allele frequency > 1%.22 Genetic scores were calculated as the sum of the number of risk alleles for all genetic variants related to each transporter in a participant. The genetic score was represented in the results as a genetic score if the number of score values were ≤5. Otherwise, we represented them in quartiles. We considered a risk allele to be

the allele associated with any of these five theoretical situations potentially related to an increased exposure of the drug to the foetus: decreased function of the transporter, declined expression of the transporter, non-resistance to the treatment, higher concentrations of the drug, or more adverse effects. Information related to the studies is available in Supplemental Table 2.

Ethical approval

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

The MoBa study is conducted according to the Declaration of Helsinki for medical research involving human subjects. The establishment of MoBa and initial data collection was based on a license from the Norwegian Data Protection Agency. It is now based on regulations related to the Norwegian Health Registry Act. Participants provided written informed consent before joining the cohort. This project was approved by the Regional Committee for Medical and Health Research Ethics of South/East Norway (reference: 2017/1362).

Statistical analyses

Normally distributed continuous variables were described by means and standard deviations, nonnormally distributed continuous variables by medians and 25th-75th percentiles, and categorical variables by proportions.

We first assessed the relationship between maternal use of centrally acting drugs during pregnancy and birth weight using multivariable linear regressions adjusted for offspring sex and maternal factors (age at delivery, years of education, pre-pregnancy body mass index, parity and having ever smoked). Clustered standard errors were computed to account for dependence among births to mothers contributing with more than one pregnancy in MoBa. To determine whether there were significant interactions between maternal prenatal use of centrally acting drugs and the genetic scores on the offspring birth weight, we applied likelihood ratio tests between nested linear regression models with and without an interaction product-term of "exposure group x genetic score".

202

203

204

205

206

207

208

209

210

211

The nested models were further adjusted for the first twenty ancestry-informative genetic principal components and genotyping batch. We considered any interaction with a pvalue for the overall interaction test < 0.05 and a differential association between medication use and offspring birth weight in the two extreme categories according to the genetic score. Whether an interaction was found, we further explored interactions with the individual variants in the genetic score as sensitivity analyses using the same strategy (as these were exploratory sensitivity analyses, we here considered any interaction with a p-value < 0.1). Statistical analyses were performed in R Software, version 4.1.0. Our analysis code is available in GitHub:

https://github.com/alvarohernaez/Gene psychoactivedrug BW MoBa/.

RESULTS

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

Study population

In our study, we included 69,828 singleton pregnancies with offspring genotype information and offspring birth weight, and 81,189 singleton pregnancies with maternal genotype data and offspring birth weight (Figure 1). Mean birth weight was 3,639 grams (SD 522). A total of 174 children (0.25%) were exposed to maternal use of antiseizure drugs during pregnancy and 766 (1.10%) to antidepressants. Women using centrally acting drugs were younger (only for antiseizure drugs), had lower educational attainment, and were more likely to have ever smoked (Table 1).

Figure 1. Flow chart of study participants.




Table 1. Baseline characteristics of mothers with offspring genotype information.

	Antiseizure drugs Antidepre			essants	
	Exposed	Unexposed	Exposed	Unexposed	
	(n = 174)	(n = 69,654)	(n = 766)	(n = 69,062)	
Age at delivery (years), mean ± SD	29.1 ± 4.83	30.2 ± 4.52	30.2 ± 5.07	30.2 ± 4.51	
Education years, mean ± SD	15.9 ± 3.64	17.1 ± 3.30	16.2 ± 3.63	17.2 ± 3.30	
Pre-pregnancy body mass index (kg/m²), median (25th-75th	23.3 (21.6-26.4)	23.3 (21.1-25.9)	23.2 (21.1-26.6)	23.1 (21.1-25.9)	
percentiles)					
Having ever smoked, n (%)	107 (61.8%)	34,310 (50.0%)	510 (67.4%)	33,907 (49.9%)	
Previous number of deliveries:					
0, <i>n</i> (%)	64 (36.8%)	23,589 (33.9%)	261 (34.1%)	23,343 (33.9%)	
1, <i>n</i> (%)	42 (24.1%)	22,342 (32.1%)	223 (29.1%)	22,113 (32.1%)	
2, n (%)	44 (25.3%)	13,697 (19.7%)	156 (20.4%)	13,547 (19.7%)	
3, <i>n</i> (%)	15 (8.62%)	6,118 (8.78%)	72 (9.40%)	6,045 (8.77%)	

≥4, <i>n</i> (%)	9 (5.17%)	3,908 (5.61%)	54 (7.05%)	3,851 (5.59%)
Offspring birth weight, mean ± SD	3,516 ± 603	3,639 ± 522	3,574 ± 512	3,640 ± 522
Biological sex of the offspring:				
Female, n (%)	84 (48.3%)	35,549 (51.0%)	366 (47.8%)	35,267 (51.1%)
Male, n (%)	90 (51.7%)	34,105 (49.0%)	400 (52.2%)	33,795 (48.9%)

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255


256

257


Search of genetic variants on placental transporters The systematic search identified 26 genetic variants in the placental transporter genes associated with differences in antiseizure drugs and/or antidepressant outcomes (Supplemental Figure 1), of which 14 were independent and available in the MoBa genotype database (Supplemental Table 1). Seven variants were found for MDR1-ABCB1, two for MRP1-ABCC1, three for MRP2-ABCC2, and two for BCRP-ABCG2. We used these genetic variants to calculate risk scores. The ranges of values for the four genetic scores calculated were: 0 to 11 (MDR1-ABCB1; we presented the stratified associations according to quartiles), 0 to 4 (MRP1-ABCC1), 2 to 6 (MRP2-ABCC2), and 0 to 4 (BCRP-ABCG2). Interaction between genetic variants of placental transporters and exposure to antiseizure drugs during pregnancy on birth weight Antiseizure medication use during pregnancy was associated with lower birth weight (-95.5 g, 95% confidence interval [CI] -190 to -0.78). Greater values of the MRP2-ABCC2 genetic score in the offspring were associated with lower birth weight in offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed was 70.3 g (95% CI -494 to 634) in the lowest genetic score category (2 risk alleles) and -306 g (95% CI -361 to -31.8) in the highest (6 risk alleles) (p-value for interaction = 0.019; Figure 2). The variant with the strongest evidence of an interaction in the sensitivity analyses of the MRP2-ABCC2 genetic score was rs3740066 (p-value for interaction = 0.023; Supplemental Figure 2). Greater values of the MDRP1-ABCB1 genetic score in the mother were also linked to lower birth weight among offspring of mothers who used antiseizure drugs during pregnancy. The difference in birth weight between exposed vs. unexposed were -66.8 g (95% CI -225 to 91.2) in the lowest genetic score category (first quartile) and -317 g (95% CI -517 to -117) in the highest (fourth quartile) (p-value for interaction = 0.037; Figure 3). Variants rs10248420 and rs2235015 included in the MDRP1-ABCB1

258 genetic score had some evidence of an interaction in the sensitivity analyses (p-values

for interactions = 0.042 and 0.058, respectively; Supplemental Figure 3).







267

268

269

270

271

Interaction between genetic variants of placental transporters and exposure to antidepressants during pregnancy on birth weight Use of antidepressant drugs during pregnancy was associated with lower birth weight (-60.5 g, 95% CI -97.6 to -23.3). However, we observed no interactions between prenatal use of antidepressants and any genetic score of placental efflux transporters (in offspring or mothers) on birth weight in the offspring (Supplemental Figures 4 and 5).

DISCUSSION

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

In this large population-based study, involving offspring of mothers who used antiseizure medication during pregnancy, a high genetic score for MRP2-*ABCC2* in the offspring and MDR1-*ABCB1* in the mother, suggesting a greater exposure to these drugs, was associated with lower birth weight in the offspring.

MDR1-ABCB1 and MRP2-ABCC2 are the only transporters located in the apical membrane of the trophoblast (maternal side) and their function is to return xenobiotics to maternal circulation.²³ Thus, it seems plausible that genetic variants linked to lower transporter activity are associated with higher foetal exposure and greater toxicity of antiseizure drugs. In addition, the main variant in the interaction between the MRP2-ABCC2 genetic score and prenatal antiseizure drug use (rs3740066) has been previously linked to a poorer response to antiseizure medication²⁴ and a higher risk of other adverse events during pregnancy (intrahepatic cholestasis of pregnancy).²⁵ The differences in the interactions found within genetic variants in the offspring (MRP2-ABCC2) and maternal genome (MDR1-ABCB1) can be explained by physiological changes in the placenta structure. Early in pregnancy, the separation between the maternal circulation and the foetal circulation by the trophoblasts villous barrier is 50-100 µm (second month). It becomes progressively thinner as the pregnancy proceeds (only 4-5 µm at term).26 In addition, the total placenta surface area increases from about 5 m² at 28 weeks of gestation to 12 m² at term. Thus, passive diffusion of medications increases with gestational age, which means that medication can reach the foetal circulation more easily later in pregnancy.²⁶ At the same time, the expression of MRP2-ABCC2 increases with advancing gestational age, whereas the expression of MDR1-ABCB1 declines.^{27,28} As a consequence of all these phenomena, the presence of risk alleles for MRP2-ABCC2 may play a more significant role in determining the offspring's exposure. However, an alternative hypothesis could also explain our findings. A greater foetal exposure to medication due to lower activity of the efflux transporters may also be linked to lower medication levels in the mother and a poorer control of the disease. Greater disease effects in mothers may be

associated with alternative mechanisms that may also explain an increased risk of low birth weight in the offspring.

There could be several reasons for the lack of gene-drug interactions with antidepressants. First, the association between exposure to antidepressants during pregnancy and birth weight is of a smaller magnitude in our data, which can make the search of genedrug interactions more challenging. Second, the accuracy of our data regarding the usage of antidepressants may be less precise, as women may have varying criteria for identifying such treatments. This discrepancy may not be present regarding antiseizure drugs. Finally, a larger proportion of women may discontinue the use of antidepressants during pregnancy compared to antiseizure medications.²⁹

Our study has some limitations. First, due to the unavailability of information on the specific drug utilized, we conducted our analysis based on aggregated drug groups. Although the main medications in each group show similar pharmacodynamic behaviour and their usage during pregnancy reduces the number of medications under consideration,³ this may interfere with our findings because there may be variations in the medication groups' interactions due to differences in transporter affinity or dose-dependent effects.^{26,30} Second, due to the lack of a genome-wide association study showing which genetic variants are associated with high or low activity of efflux transporters, we calculated risk scores using studies on genetic variants indirectly related to high or low activity (e.g., treatment resistance, treatment efficacy, presence of adverse effects). Third, the interactions found in our data are only suggestive and our findings require replication in independent populations to confirm their validity. Finally, the characteristics of our participants (individuals of northern European ancestry with moderate-high socioeconomic status) limit our capacity to generalize our conclusions to other populations.

CONCLUSIONS

In summary, genetic variants in MRP2-ABCC2 and MDR1-ABCB1 placental transporters may modulate the association between prenatal exposure to antiseizure drugs and low birth weight in the offspring. To the best of our knowledge, this is the largest gene-drug interaction study on offspring birth weight to date and it was performed in a well-characterized population with genome-wide genotype information. If our findings are confirmed, particularly in studies in which we know exactly which drug the mothers have used during pregnancy, the assessment of these genetic variants may be implemented in clinical settings to support safer use of antiseizure drugs during pregnancy.

DATA AVAILABILITY STATEMENT

Consent given by the participants does not open for storage of data on an individual level in repositories or journals. Researchers who want access to datasets for replication should apply to datatilgang@fhi.no. Access to datasets requires approval from the Regional Committee for Medical and Health Research Ethics in Norway and an agreement with MoBa.

ACKNOWLEDGMENTS

The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research. We thank all the participating families in Norway who take part in this ongoing cohort study, and those who contributed to the recruitment and the infrastructure of the cohort.

We thank the Norwegian Institute of Public Health for generating high-quality genomic data. This research is part of the HARVEST collaboration, supported by the Research Council of Norway (project reference: #229624). We also thank the NORMENT Centre for providing genotype data, funded by the Research Council of Norway (project reference: #223273), South East Norway Health Authority, and Stiftelsen Kristian Gerhard Jebsen. We further thank the Center for Diabetes Research (University of Bergen) for providing genotype data funded by the European Research Council Advanced Grant project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, the Trond Mohn Foundation, the Research Council of Norway, the Novo Nordisk Foundation, the University of Bergen, and the Western Norway Health Authority.

This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated, and developed by the TSD service group at the University of Oslo, IT-Department (tsd-drift@usit.uio.no).

This paper does not necessarily reflect the position or policy of the Norwegian Research Council.

FUNDING

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

The MoBa Cohort Study is supported by the Norwegian Ministry of Health and Care Services and the Norwegian Ministry of Education and Research. This project received funding from the European Research Council under the European Union's Horizon 2020 research and innovation program (grant agreement No 947684). This work was also partly supported by the Research Council of Norway through its Centres of Excellence funding scheme, project number 262700 and 223273, and the project "Women's fertility - an essential component of health and well-being", number 320656, and co-funded by the European Research Council (grant agreement No 101071773). M.H.H. was supported by the fellowship "Estancias de movilidad Jose Castillejo dentro del Programa Estatal de Promoción del Talento y su empleabilidad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020", from the Spanish government. P.R.N. was supported by the European Research Council (grant agreement No 293574), the Novo Nordic Foundation (#NNF19OC0054741) and the Trond Mohn Foundation (PRECISE-DIA). E.C. and A.Havdahl were supported by the Research Council of Norway (274611) and the South-Eastern Norway Regional Health Authority (project numbers 2020022, 2021045). O.A.A. was supported by the European Research Council (grant agreement No 964874) and the Research Council of Norway (300309, 273291). The funders had no role in the study design; the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Views and opinions expressed in this paper are those of the authors only and do not necessarily reflect those of the funders. Neither the European Union nor the granting authority can be held responsible for them.

CONFLICTS OF INTEREST

O.A.A. is a consultant for cortechs.ai and has received speaker's honorarium from Janssen, Lundbeck, and Sunovion unrelated to the current work. The rest of the authors declare that no competing interests exist.

AUTHORS' CONTRIBUTION

M.H.H. conceived and designed the study, was responsible for data curation, formal analyses, data interpretation, and drafting the article. J.M.C. critically revised the article and contributed to interpretation of the data. K.H.S. provided support in data analysis, software use, and visualization of results, and critically revised the article. T.K.W.G. was involved in the interpretation of data and critically revised the article. Y.L. contributed to data acquisition and critically revised the article. P.M. contributed to data acquisition and critically revised the article. P.R.N. contributed to data acquisition and critically revised the article. O.A.A. contributed to data acquisition and critically revised the article. E.C. contributed to data acquisition and critically revised the article. E. Molden critically revised the article. S.E.H. contributed to data acquisition, obtained funding, and critically revised the article. K.F. provided support in data analysis and critically revised the article. M.C.M. and A.Hernaez coordinated the project, contributed to data interpretation, and critically revised the article. M.H.H. and A.Hernaez are the guarantors of this study, accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish.

REFERENCES

- 407 F, 1. Benevent J, Montastruc Damase-Michel C. The importance of
- 408 pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017;16:
- 409 1181-1190. doi:10.1080/14740338.2017.1363177
- 410 Molenaar NM, Bais B, Lambregtse-van den Berg MP, Mulder CL, Howell EA, Fox NS, 2.
- 411 et al. The international prevalence of antidepressant use before, during, and after pregnancy:
- 412 A systematic review and meta-analysis of timing, type of prescriptions and geographical
- 413 variability. J Affect Disord. 2020;264: 82-89. doi:10.1016/j.jad.2019.12.014
- 414 Cohen JM, Cesta CE, Furu K, Einarsdóttir K, Gissler M, Havard A, et al. Prevalence 3.
- 415 trends and individual patterns of antiepileptic drug use in pregnancy 2006-2016: A study in the
- 416 five Nordic countries, United States, and Australia. Pharmacoepidemiol Drug Saf. 2020;29:
- 417 913-922. doi:10.1002/pds.5035
- 418 Margulis AV, Hernandez-Diaz S, McElrath T, Rothman KJ, Plana E, Almqvist C, et al. 4.
- Relation of in-utero exposure to antiepileptic drugs to pregnancy duration and size at birth. 419
- 420 PLoS One. 2019;14: e0214180. doi:10.1371/journal.pone.0214180
- 421 5. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects
- 422 with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261: 579-588.
- 423 doi:10.1007/s00415-013-7239-x
- 424 6. Wartko PD, Weiss NS, Enquobahrie DA, Chan KCG, Stephenson-Famy A, Mueller BA,
- 425 et al. Association of antidepressant continuation in pregnancy and infant birth weight. J Clin
- 426 Psychopharmacol. 2021; Publish Ahead of Print: 403. doi:10.1097/jcp.00000000001410
- 427 7. Ashorn P, Ashorn U, Muthiani Y, Aboubaker S, Askari S, Bahl R, et al. Small vulnerable
- 428 newborns—big potential for impact. Lancet. 2023;401: 1692-1706. doi:10.1016/s0140-
- 429 6736(23)00354-9
- 430 8. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta:
- 431 impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol. 2006;2: 51-69.
- 432 doi:10.1517/17425255.2.1.51

- 433 Wang J-S, Newport DJ, Stowe ZN, Donovan JL, Pennell PB, DeVane CL. The 9.
- 434 emerging importance of transporter proteins in the psychopharmacological treatment of the
- 435 pregnant patient. Drug Metab Rev. 2007;39: 723-746. doi:10.1080/03602530701690390
- 436 10. Joshi AA, Vaidya SS, St-Pierre MV, Mikheev AM, Desino KE, Nyandege AN, et al.
- 437 Placental ABC transporters: Biological impact and pharmaceutical significance. Pharm Res.
- 438 2016;33: 2847-2878. doi:10.1007/s11095-016-2028-8
- 439 11. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human
- 440 placenta. Clin Pharmacokinet. 2004;43: 487-514. doi:10.2165/00003088-200443080-00001
- 441 Wolking S. Schaeffeler E. Lerche H. Schwab M. Nies AT. Impact of genetic 12.
- 442 polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical
- 443 implications: Update of the literature. Clin Pharmacokinet. 2015;54:
- 444 doi:10.1007/s40262-015-0267-1
- 445 Goetzl L. Darbinian N. Merabova N. Devane LC, Ramamoorthy S. Gestational age
- 446 variation in human placental drug transporters. Front Pharmacol. 2022;13.
- 447 doi:10.3389/fphar.2022.837694

- 448 14. Daud ANA, Bergman JEH, Bakker MK, Wang H, de Walle HEK, Plösch T, et al.
- Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental 449
- 450 transporter proteins. Pharmacogenomics. 2014;15: 1029-1041. doi:10.2217/pgs.14.62
- 451 Ewing G, Tatarchuk Y, Appleby D, Schwartz N, Kim D. Placental transfer of
- 452 antidepressant medications: Implications for postnatal adaptation syndrome.
- 453 Pharmacokinet. 2015;54: 359-370. doi:10.1007/s40262-014-0233-3
- 454 Paltiel L, Haugan A, Skjerden T, et al. The biobank of the Norwegian Mother and Child 16.
- 455 Cohort Study-present status. Norsk Epidemiologi. 2014;24: 29-35. Available:
- 456 https://www.ntnu.no/ojs/index.php/norepid/article/view/1755/1752
- Corfield EC, Frei O, Shadrin AA, Rahman Z, Lin A, Athanasiu L, et al. The Norwegian 458 17.
- 459 Mother, Father, and Child cohort study (MoBa) genotyping data resource: MoBaPsychGen
- 460 pipeline v.1. bioRxiv. 2022. p. 2022.06.23.496289. doi:10.1101/2022.06.23.496289

- 461 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The 18.
- 462 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement:
- 463 guidelines for reporting observational studies. J Clin Epidemiol. 2008;61: 344-349.
- 464 doi:10.1016/j.jclinepi.2007.11.008
- Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, et al. Cohort profile 465 19.
- 466 update: The Norwegian mother and child cohort study (MoBa). Int J Epidemiol. 2016;45: 382-
- 467 388. doi:10.1093/ije/dyw029
- 468 20. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and
- 469 surveillance throughout 30 years: Thirty years' birth registration. Acta Obstet Gynecol Scand.
- 470 2000;79: 435–439. doi:10.1034/j.1600-0412.2000.079006435.x
- 471 21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
- 472 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.
- 473 2021;372: n71. doi:10.1136/bmj.n71
- 474 22. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-
- 475 specific haplotype structure and linking correlated alleles of possible functional variants.
- 476 Bioinformatics. 2015;31: 3555–3557. doi:10.1093/bioinformatics/btv402
- 477 23. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. Absence or
- 478 pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug
- 479 exposure. J Clin Invest. 11 1999;104: 1441-1447. doi:10.1172/jci7963
- 480 24. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms and
- 481 haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2
- 482 polymorphisms and epilepsy drug resistance. CNS Neurosci Ther. 2012;18: 647-651.
- 483 doi:10.1111/j.1755-5949.2012.00336.x
- 484 25. Sookoian S, Castaño G, Burgueño A, Gianotti TF, Pirola CJ. Association of the
- 485 multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis
- of pregnancy. J Hepatol. 2008;48: 125-132. doi:10.1016/j.jhep.2007.08.015 486
- 487 26. Al-Enazy S, Ali S, Albekairi N, El-Tawil M, Rytting E. Placental control of drug delivery.
- 488 Adv Drug Deliv Rev. 2017;116: 63-72. doi:10.1016/j.addr.2016.08.002

489 27. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, 490 Fusch C, et al. Variable expression of mrp2 (abcc2) in human placenta: Influence of gestational 491 and cellular differentiation. Drug Dispos. 2005;33: age Metab 896-904. 492 doi:10.1124/dmd.104.003335 493 Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. Expression of the 28. 494 multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases 495 with advancing gestation. Placenta. 2006;27: 602-609. doi:10.1016/j.placenta.2005.05.007 496 29. Cohen JM, Selmer R, Furu K, Karlstad Ø. Interrupted time series analysis to assess 497 changes in prescription filling around conception and implications for exposure 498 misclassification. Pharmacoepidemiol Drug Saf. 2020;29: 745-749. doi:10.1002/pds.4974 499 Staud F, Cerveny L, Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and 30. 500 SLC transporters on drug transport across the placenta and fetal drug exposure. J Drug Target.

2012;20: 736-763. doi:10.3109/1061186x.2012.716847

501

SUPPORTING INFORMATION

TABLE OF CONTENTS

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

SUPPLEMENTAL TABLES.......31 Supplemental Table 1. Expected risk allele for birth weight in efflux transporters.......31 Supplemental Table 2. The articles detail the development of the expected risk allele for **Supplemental Figure 1**. Flow chart of the systematic literature review of genetic variants on placental efflux transporters......36 Supplemental Figure 2. Differences in birth weight associated with pregnancy use of antiseizure drugs due to ABCC2 individual genetic variants in the offspring.37 Supplemental Figure 3. Differences in birth weight associated with pregnancy use of Supplemental Figure 4. Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the offspring.......39 Supplemental Figure 5. Differences in birth weight associated with pregnancy use of antidepressant medication and placental transporter genetic scores in the mother......40

SUPPLEMENTAL REFERENCES41

SUPPLEMENTAL MATERIALS

Search strategy of genetic variants

All studies that examined the association between the placental transporters of interest and epilepsy or depression were researched. We systematically searched PubMed, Web of Science, pharmacogenetic websites (https://www.pharmgkb.org) and GWAS catalog (https://www.ebi.ac.uk/gwas/home). All databases were searched using the Boolean method with the following terms (1 AND 2 AND 3): 1) "antiseizure" OR "antiepilepsy" OR "anticonvulsants" OR "antidepressant" OR "benzodiazepines"; 2) "polymorphism" OR "genetic polymorphism" OR "genetic variant" OR "pharmacogenetics"; 3) "ATP binding cassette" or "ABCB1" OR "ABCC1" OR "ABCC2" OR "ABCG2" OR "ABCC5" OR "ABCC3". In addition, the reference and discussions of all pooled articles were carefully scanned for additional publications. We excluded studies: 1) not performed in humans; 2) not published in English; 3) not published in scientific journals; and 4) focused on other drug groups.

SUPPLEMENTAL TABLES

Supplemental Table 1. Expected risk allele for birth weight in efflux transporters.

							1
					Expected		Conserved after
				Expected risk	risk allele		linkage
				allele for birth	frequency in		disequilibrium block
Gene	Polymorphism	Chromosome	Position	weight	Europeans	References	analysis
ABCB1	rs1045642	7	87138645	G	0.42	(1-9)	Yes
ABCB1	rs28401781	7	87148328	Т	0.12	(10)	No
ABCB1	rs2235067	7	87149922	Т	0.13	(11)	No
ABCB1	rs4148740	7	87152103	G	0.13	(12)	No
ABCB1	rs10280101	7	87153585	С	0.13	(11)	No
ABCB1	rs7787082	7	87157051	А	0.18	(11,13)	No
ABCB1	rs2032583	7	87160561	G	0.13	(11, 14-17)	No
					A: 0.41		
ABCB1	rs2032582	7	87160618	T/A	T: 0.02	(11, 15, 18-25)	No
ABCB1	rs4148739	7	87161049	С	0.13	(10-12)	No
ABCB1	rs11983225	7	87161520	С	0.13	(11)	No
ABCB1	rs10248420	7	87164986	G	0.18	(11, 26)	Yes
ABCB1	rs2235040	7	87165750	Т	0.13	(11,15,16)	No
ABCB1	rs12720067	7	87169356	Т	0.13	(11)	No
ABCB1	rs2032588	7	87179443	G	0.94	(27)	No, SNP not in MoBa
ABCB1	rs1128503	7	87179601	G	0.58	(5,12,22)	Yes
ABCB1	rs2235015	7	87199564	А	0.21	(11,17)	Yes
ABCB1	rs9282564	7	87229440	G	0.10	(28)	Yes
ABCB1	rs10245483	7	89637608	G	0.51	(29)	Yes
ABCC1	rs875740	16	16123048	С	0.35	(30)	Yes
ABCC1	rs212090	16	16236004	А	0.46	(31,32)	Yes
ABCC2	rs717620	10	101542578	С	0.79	(33-36)	Yes
ABCC2	rs4148386	10	101548468	G	0.44	(12)	No
ABCC2	rs2273697	10	101563815	G	0.80	(12, 37)	Yes
ABCC2	rs3740066	10	101604207	С	0.63	(12,33,38)	Yes
ABCG2	rs2231142	4	89052323	Т	0.10	(39,40)	Yes
ABCG2	rs3114020	4	89083666	С	0.40	(40)	Yes
L		I	I	1	I		

Gene	Polymorphism	Drug	Study participants	Effect			Expected risk allele in the publication	Risk allele for birth weight	Reference
ABCB1		All antiseizure drugs	114 drug-resistant epilepsy patients, 213 seizure-free patients and 287 controls (Taiwan)	Efficacy	The C allele and the CC genotype were associated with drug resistance relative to the T allele and the TT genotype.	0.001	Т		1
ABCB1		All antiseizure drugs	746 patients with epilepsy and 179 controls (China)	Efficacy	The TT genotype was associated with drug resistance	0.0009	G		2
ABCB1		All antiseizure drugs	220 patients with epilepsy and 220 controls (India)	Efficacy	The TT genotype was associated with drug resistance relative to the CC genotype.	0.001	G		3
ABCB1		Carbamazepine	3,293 patients with epilepsy. Meta analysis	Pharmacokinetics/ Efficacy	The T allele was associated with lower concentrations, lower absorption, and resistance to the drug activity.	0.004	Т		4
ABCB1		Carbamazepine	2,126 patients with epilepsy. Meta-analysis	Efficacy	The T allele was associated to decreased plasma concentrations of the drug.	<0.05	G		5
ABCB1	rs1045642	Agomelatine	28 healthy volunteers (Spain)	Pharmacokinetics	The TT genotype was associated with lower concentrations or lower absorption of the drug.	0.047	G	G	6
ABCB1		All antiseizure drugs	8,716 patients with epilepsy, 4,037 drug- resistant epilepsy patients and 4,679 drug- responsive patients. Meta analysis	Efficacy	The T allele was associated with higher risk of drug resistance in the overall population and in Caucasians.	0.006	G		7
ABCB1		Carbamazepine	In vitro	Impact of T allele on the sensitivity, intracellular accumulation, and transepithelial permeability of antiseizure drugs	The recombinant T allele_cells showed higher resistance to carbamazepine compared with C allele_cells in the cytotoxicity assay. The intracellular accumulation of carbamazepine was significantly decreased in cells transfecting with recombinant T allele when compared with recombinant C allele_cells.	0.01	G		8
ABCB1		Carbamazepine	210 patients with epilepsy (China)	Pharmacokinetics	The GG genotype was associated with increased concentrations of carbamazepine relative to the AG genotype.	0.001	G		9
ABCB1	rs10248420	All antidepressants	256 patients with epilepsy (Europe)	Efficacy	The G allele was associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine relative to the A allele.	0.0095	G	G	11
ABCB1		Olanzapine	80 healthy volunteers (Spain)	Efficacy	The A allele was associated with decreased drug response compared to the G allele	0.047	G		26
ABCB1		All antiseizure drugs	90 patients with epilepsy (USA)	Pharmacokinetics	AA and AG genotypes were associated with increased clearance of carbamazepine relative to the GG genotype.	0.036	G		12
ABCB1	rs1128503	Lamotrigine	222 patients with epilepsy (Croatia)	Pharmacokinetics	The genotype CC was associated with higher lamotrigine concentrations compared to CT and TT genotypes.	0.021	G	G	22
ABCB1		Carbamazepine	2,126 patients with epilepsy. Meta-analysis	Efficacy	The CC genotype was associated with lower resistance to carbamazepine.	0.03	G		5
ABCB1	rs2235015	All antidepressants	339 patients with depression (European)	Efficacy	The A allele was associated with higher remission for P- glycoprotein antidepressants, citalopram, paroxetine, amitriptyline, and venlafaxine, relative to the C allele.	0.025	А	А	11

Gene	Polymorphism	Drug	Study participants		Effect	P-value	Expected risk allele in the publication	Risk allele for birth weight	Reference
ABCB1		All antidepressants	73 patients with depressive disorder (Germany)	Efficacy	The A allele was associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine, relative to the C allele.	0.030	А		17
ABCB1	rs9282564	Paroxetine	71 psychiatric patients (Switzerland)	Efficacy	The G allele was associated with greater clinical response.	0.043	G	G	28
ABCB1	rs10245483	All antidepressants	683 patients with major depressive disorder (multisite)	Efficacy	The T allele was associated with less remission.	0.001	G	G	29
ABCC1	rs875740	All antiseizure drugs	199 patients from the Mayo Clinic Bipolar Disorder Biobank GWAS (USA)	Efficacy	The C allele was associated with better treatment response.	0.0089	С	С	30
ABCC1		Clozapine	137 medicated patients (Australia)	Adverse effects	The A allele was associated with higher diastolic blood pressure (adverse effect)	0.01	А		31
ABCC1	rs212090	All antidepressants	148 patients with major depressive disorder (Australia)	Efficacy	The A allele was included int the pharmacogenetic guide group and associated with greater remission	0.0001	А	А	32
ABCC2		All antiseizure drugs	537 patients with epilepsy (217 drug resistant patients and 320 drug responders) (China)	Efficacy	The TT genotype was associated with drug resistance	0.001	С		33
ABCC2	rs717620	All antiseizure drugs	4,300 patients with epilepsy (2,261 drug- resistant patients and 2,039 drug-responsive patients). Meta-analysis	Efficacy	The T allele was associated with drug resistance	drug resistance 0.0006 C	С	34	
ABCC2		All antiseizure drugs	254 patients with epilepsy (104 drug-resistant and 150 drug-responsive) (China) The TT genotype was associated with drug resistance, relative to the CC genotype	0.001	С		35		
ABCC2		All antiseizure drugs	1,842 patients with epilepsy. Meta-analysis	Efficacy	The T allele was associated with drug resistance.	0.002	С		36
ABCC2	0070007	All antiseizure drugs	90 patients with epilepsy (USA)	Pharmacokinetics	AA and AG genotypes were associated with higher drug clearance relative to the GG genotype.	<0.05 G	G	_	12
ABCC2	rs2273697	All antiseizure drugs	453 patients with epilepsy (China)	Efficacy	The A allele A was associated with drug resistance.	0.001	G	G	37
ABCC2		All antiseizure drugs	90 patients with epilepsy (USA)	Pharmacokinetics	The G allele was associated with lower carbamazepine-10, 11-epoxide (metabolite): carbamazepine ratio.	0.008	С		12
ABCC2	rs3740066	All antiseizure drugs	537 patients with epilepsy (217 drug resistant patients and 320 drug responders) (China)	Efficacy	CT and TT genotypes were associated with drug resistance relative to CC genotype.	0.038	С	С	33
ABCC2		No drug	In vitro study	In vitro function of the transporter	The T allele was associated with a decreased function of the transporter.	0.017	С		38

Gene	Polymorphism	Drug	Study participants		Effect			Risk allele for birth weight	Reference
ABCG2	rs2231142	Lamotrigine	112 patients with epilepsy (China)	Pharmacokinetics	The TT genotype was associated with increased concentrations of lamotrigine relative to GG and GT genotypes.	0.015	Т	Т	39
ABCG2		Lamotrigine	140 patients with epilepsy (China)	Pharmacokinetics	CA and AA genotypes were associated with higher concentrations of lamotrigine relative to the CC genotype.	<0.05	Т		40
ABCG2	rs3114020	Lamotrigine	140 patients with epilepsy (China)	Pharmacokinetics	CC and CT genotypes were associated with increased concentrations of lamotrigine relative to the TT genotype.	0.01	С	С	40

Supplemental Table 3. STROBE checklist for cohort studies

	Item No	Recommendation	Page No
Title and abstract			
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	3-4
Introduction			•
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	6-7
Objectives Methods	3	State specific objectives, including any pre-specified hypotheses	6-7
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	8
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	8-9
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	9-11
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-11
Bias	9	Describe any efforts to address potential sources of bias	9-11
Study size	10	Explain how the study size was arrived at	Fig.1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10-11
		(b) Describe any methods used to examine subgroups and interactions	10-11
		(c) Explain how missing data were addressed	-
		(d) If applicable, explain how loss to follow-up was addressed	-
		(e) Describe any sensitivity analyses	11
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed (b) Give reasons for non-participation at each stage	Fig. 1
Descriptive data	14*	(c) Consider use of a flow diagram (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information	11, Table
		on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest	1 -
		(c) Summarize follow-up time (e.g., average and total amount)	_
Outcome data	15	Report numbers of outcome events or summary measures over time	
			14-18
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included	14-18 Figures 2,3
		(b) Report category boundaries when continuous variables were categorized	14-18 Figures 2,3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	18, Suppleme ntal
Discussion			figures 2-5
Key results	18	Summarize key results with reference to study objectives	19
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.	
Interpretation	20	Discuss both direction and magnitude of any potential bias Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of	20
	21	analyses, results from similar studies, and other relevant evidence	19-20
Generalizability Other information	<u> </u> 21	Discuss the generalizability (external validity) of the study results	20
	22	City the source of funding and the role of the fundamental the process study and if and include for	
Funding 550	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

SUPPLEMENTAL RESULTS

551


552

553

554

555


Supplemental Figure 1. Flow chart of the systematic literature review of genetic variants on placental efflux transporters.




Supplemental Figure 2. Differences in birth weight associated with pregnancy use of antiseizure drugs due to ABCC2 individual genetic variants in the offspring.

556


557



Difference in birth weight in users vs. non-users of antiseizure drugs in pregnancy (95% confidence interval)




Difference in birth weight in users vs. non-users of antiseizure drugs in pregnancy (95% confidence interval)



Difference in birth weight in users vs. non-users of antiseizure drugs in pregnancy (95% confidence interval)

Supplemental Figure 3. Differences in birth weight associated with pregnancy use of


antiseizure drugs due to ABCB1 individual genetic variants in the mother.





559


560

561












Difference in birth weight in users vs. non-users of antiseizure drugs in pregnancy (95% confidence interval)



Difference in birth weight in users vs. non-users of antiseizure drugs in pregnancy (95% confidence interval)



Difference in birth weight in users vs.non-users of antiseizure drugs in pregnancy (95% confidence interval)



Difference in birth weight in users vs.non-users of antiseizure drugs in pregnancy (95% confidence interval)

563

SUPPLEMENTAL REFERENCES

567

- 569 1. Hung C-C, Jen Tai J, Kao P-J, Lin M-S, Liou H-H. Association of polymorphisms
- 570 inNR1I2andABCB1genes with epilepsy treatment responses. Pharmacogenomics.
- 571 2007;8: 1151–1158. doi:10.2217/14622416.8.9.1151
- 572 2. Kwan P, Baum L, Wong V, Ng PW, Lui CHT, Sin NC, et al. Association between
- 573 ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy
- 574 Behav. 2007;11: 112-117. doi:10.1016/j.yebeh.2007.04.013
- 575 3. Shaheen U, Prasad DKV, Sharma V, Suryaprabha T, Ahuja YR, Jyothy A, et al.
- 576 Significance of MDR1 gene polymorphism C3435T in predicting drug response in
- 577 epilepsy. Epilepsy Res. 2014;108: 251-256. doi:10.1016/j.eplepsyres.2013.11.009
- 578 4. Zhang M-L, Chen X-L, Bai Z-F, Zhao X, Li W-X, Wang X-Y, et al. ABCB1 c.3435C
- 579 > T and EPHX1 c.416A > G polymorphisms influence plasma carbamazepine
- 580 concentration, metabolism, and pharmacoresistance in epileptic patients. Gene.
- 581 2021;805: 145907. doi:10.1016/j.gene.2021.145907
- 582 5. Fan Y-X, Zhang Z, Meng J-R, Yin S-J, Wang P, Zhou T, et al. Association of
- 583 ABCB1 polymorphisms with carbamazepine metabolism and resistance in epilepsy: A
- 584 meta-analysis. Epilepsy Res. 2021;177: 106785. doi:10.1016/j.eplepsyres.2021.106785
- 585 6. Saiz-Rodríguez M, Ochoa D, Belmonte C, Román M, Vieira de Lara D, Zubiaur
- 586 P, et al. Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine
- 587 pharmacokinetics. Psychopharmacol. 2019;33: 522-531.
- 588 doi:10.1177/0269881119827959
- 589 7. Li M, Tan J, Yang X, Su L, Xie J, Liang B, et al. The ABCB1-C3435T
- 590 polymorphism likely acts as a risk factor for resistance to antiepileptic drugs. Epilepsy
- 591 Res. 2014;108: 1052-1067. doi:10.1016/j.eplepsyres.2014.03.019

- 592 Shen X-M, Cheng J. Effects of MDR1 (C3435T) polymorphism on resistance, 8.
- 593 uptake, and efflux to antiepileptic drugs. DNA Cell Biol. 2019;38: 250-255.
- 594 doi:10.1089/dna.2018.4553
- 595 9. Zhu X, Yun W, Sun X, Qiu F, Zhao L, Guo Y. Effects of major transporter and
- 596 metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese
- 597 patients Pharmacogenomics. 1867-1879. with epilepsy. 2014;15:
- 598 doi:10.2217/pgs.14.142
- 599 10. Huang X, Yu T, Li X, Cao Y, Li X, Liu B, et al. ABCB6, ABCB1 and ABCG1 genetic
- 600 polymorphisms and antidepressant response of SSRIs in Chinese depressive patients.
- 601 Pharmacogenomics. 2013;14: 1723–1730. doi:10.2217/pgs.13.151
- 602 11. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms
- 603 in the drug transporter gene ABCB1 predict antidepressant treatment response in
- 604 depression. Neuron. 2008;57: 203-209. doi:10.1016/j.neuron.2007.11.017
- 605 12. Puranik YG, Birnbaum AK, Marino SE, Ahmed G, Cloyd JC, Remmel RP, et al.
- 606 Association of carbamazepine major metabolism and transport pathway gene
- 607 polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics.
- 608 2013;14: 35-45. doi:10.2217/pgs.12.180
- 609 13. Lee S-T, Ryu S, Kim S-R, Kim M-J, Kim S, Kim J-W, et al. Association study of
- 610 27 annotated genes for clozapine pharmacogenetics: Validation of preexisting studies
- 611 and identification of a new candidate gene, ABCB1, for treatment response. J Clin
- 612 Psychopharmacol. 2012;32: 441–448. doi:10.1097/jcp.0b013e31825ac35c
- 613 14. Breitenstein B, Brückl TM, Ising M, Müller-Myhsok B, Holsboer F, Czamara D.
- 614 ABCB1gene variants and antidepressant treatment outcome: A meta-analysis. Am J
- 615 Med Genet B Neuropsychiatr Genet. 2015;168: 274–283. doi:10.1002/ajmg.b.32309

- 616 15. de Klerk OL, Nolte IM, Bet PM, Bosker FJ, Snieder H, den Boer JA, et al. ABCB1
- 617 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large
- 618 sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013;13:
- 619 349-353. doi:10.1038/tpj.2012.16
- 620 16. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM.
- 621 ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression.
- 622 Pharmacogenet Genomics. 2010;20: 467-475. doi:10.1097/fpc.0b013e32833b593a
- 623 17. Breitenstein B, Scheuer S, Brückl TM, Meyer J, Ising M, Uhr M, et al. Association
- 624 of ABCB1 gene variants, plasma antidepressant concentration, and treatment response:
- 625 Results from a randomized clinical study. J Psychiatr Res. 2016;73: 86-95.
- 626 doi:10.1016/j.jpsychires.2015.11.010
- 627 18. Gassó P, Rodríguez N, Mas S, Pagerols M, Blázquez A, Plana MT, et al. Effect
- 628 of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and
- 629 clinical improvement in children and adolescent patients. Pharmacogenomics J.
- 2014;14: 457–462. doi:10.1038/tpj.2014.12 630
- 631 19. Glauser TA, Holland K, O'Brien VP, Keddache M, Martin LJ, Clark PO, et al.
- 632 Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy: CAE
- 633 Pharmacogenetics. Ann Neurol. 2017;81: 444–453. doi:10.1002/ana.24886
- 634 20. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, et al. ABCB1
- 635 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in
- 636 patients with major depressive disorder. Progress in Neuro-Psychopharmacology and
- 637 Biological Psychiatry. 2008;32: 398–404. doi:10.1016/j.pnpbp.2007.09.003
- 638 21. Mittal B, Kumari R, Lakhan R, Garg RK, Kalita J, Misra UK. Pharmacogenomic
- 639 association study on the role of drug metabolizing, drug transporters and drug target
- 640 gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian J Hum
- 641 Genet. 2011;17: 32. doi:10.4103/0971-6866.80357

- 642 22. Lovrić M, Božina N, Hajnšek S, Kuzman MR, Sporiš D, Lalić Z, et al. Association
- 643 between lamotrigine concentrations and ABCB1 polymorphisms in patients with
- 644 epilepsy. Ther Drug Monit. 2012;34: 518-525. doi:10.1097/ftd.0b013e31826517c6
- 645 23. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, et al. The
- 646 predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for
- 647 risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug
- 648 reactions. Pharmacogenomics J. 2018;18: 422-430. doi:10.1038/tpj.2017.38
- 649 24. Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, Allencherry PM, et al.
- 650 Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by
- 651 ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics.
- 652 2012;13: 1119-1127. doi:10.2217/pgs.12.86
- 653 Subenthiran S, Abdullah NR, Muniandy PK, Joseph JP, Cheong KC, Ismail Z, et 25.
- 654 al. G2677T polymorphism can predict treatment outcome of Malaysians with complex
- 655 partial seizures being treated with Carbamazepine. Genet Mol Res. 2013;12: 5937-
- 5944. doi:10.4238/2013.november.26.3 656
- 657 Zubiaur P, Soria-Chacartegui P, Koller D, Navares-Gómez M, Ochoa D, 26.
- 658 Almenara S, et al. Impact of polymorphisms in transporter and metabolizing enzyme
- 659 genes on olanzapine pharmacokinetics and safety in healthy volunteers. Biomed
- Pharmacother. 2021;133: 111087. doi:10.1016/j.biopha.2020.111087 660
- 661 27. Bet PM, Verbeek EC, Milaneschi Y, Straver DBM, Uithuisie T, Bevova MR, et al.
- 662 A common polymorphism in the ABCB1 gene is associated with side effects of PGP-
- 663 dependent antidepressants in a large naturalistic Dutch cohort. Pharmacogenomics J.
- 664 2016;16: 202-208. doi:10.1038/tpj.2015.38
- 665 28. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry J-M, Bondolfi G, et al.
- 666 CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and

- 667 therapeutic Drug Monit. 2008;30: 474-482. response. Ther
- 668 doi:10.1097/ftd.0b013e31817d6f5d
- 669 29. Schatzberg AF, DeBattista C, Lazzeroni LC, Etkin A, Murphy GM Jr, Williams LM.
- 670 ABCB1 genetic effects on antidepressant outcomes: A report from the iSPOT-D trial. Am
- 671 J Psychiatry. 2015;172: 751–759. doi:10.1176/appi.ajp.2015.14050680
- 672 30. Ho AM-C, Coombes BJ, Nguyen TTL, Liu D, McElroy SL, Singh B, et al. Mood-
- 673 stabilizing antiepileptic treatment response in bipolar disorder: A genome-wide
- association study. Clin Pharmacol Ther. 2020;108: 1233-1242. doi:10.1002/cpt.1982 674
- 675 31. Piatkov I, Caetano D, Assur Y, Lau SL, Jones T, Boyages SC, et al. ABCB1 and
- 676 single-nucleotide polymorphisms in patients treated with
- 677 Pharmgenomics Pers Med. 2017;10: 235–242. doi:10.2147/pgpm.s142314
- 678 32. Singh AB. Improved antidepressant remission in major depression via a
- 679 pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol
- 680 Neurosci. 2015;13: 150-156. doi:10.9758/cpn.2015.13.2.150
- 681 33. Qu J, Zhou B-T, Yin J-Y, Xu X-J, Zhao Y-C, Lei G-H, et al. ABCC2 polymorphisms
- 682 and haplotype are associated with drug resistance in Chinese epileptic patients: ABCC2
- 683 polymorphisms and epilepsy drug resistance. CNS Neurosci Ther. 2012;18: 647–651.
- 684 doi:10.1111/j.1755-5949.2012.00336.x
- 685 Qian L, Fang S, Yan Y-L, Zeng S-S, Xu Z-J, Gong Z-C. The ABCC2 c.-24C > T 34.
- polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis. J 686
- 687 Clin Neurosci. 2017;37: 6-14. doi:10.1016/j.jocn.2016.10.014
- 688 Xue T, Lu ZN. Association between the polymorphisms in the ATP-binding 35.
- 689 cassette genes ABCB1 and ABCC2 and the risk of drug-resistant epilepsy in a Chinese
- 690 Han population. Genet Mol Res. 2016;15. doi:10.4238/gmr15048752

- 691 36. Grover S, Kukreti R. A systematic review and meta-analysis of the role
- 692 of ABCC2 variants on drug response in patients with epilepsy. Epilepsia. 2013;54: 936—
- 693 945. doi:10.1111/epi.12132
- 694 37. Ma C-L, Wu X-Y, Zheng J, Wu Z-Y, Hong Z, Zhong M-K. Association of SCN1A,
- 695 SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in
- 696 Chinese Han patients with epilepsy. Pharmacogenomics. 2014;15: 1323-1336.
- 697 doi:10.2217/pgs.14.89
- 698 38. Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact
- 699 of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and
- 700 function. Pharmacogenomics J. 2011;11: 25-34. doi:10.1038/tpj.2010.20
- 701 39. Shen C-H, Zhang Y-X, Lu R-Y, Jin B, Wang S, Liu Z-R, et al. Specific OCT1 and
- 702 ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese
- 703 patients with epilepsy. **Epilepsy** Res. 2016;127: 186-190.
- doi:10.1016/j.eplepsyres.2016.09.004 704
- 705 40. Zhou Y, Wang X, Li H, Zhang J, Chen Z, Xie W, et al. Polymorphisms of ABCG2,
- 706 ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy
- 707 patients. Metab Pharmacokinet. 2015;30: 282-287. Drug
- 708 doi:10.1016/j.dmpk.2015.05.002